

THE EFFECT OF ARTIFICIAL SALIVA AGENT TO IMPROVE DRY MOUTH IN OVERACTIVE BLADDER PATIENTS TAKING ANTI-MUSCARINIC AGENTS: A PILOT STUDY

Hypothesis / aims of study

To investigate the effect of artificial saliva agent to improve dry mouth from anti-muscarinic agents for overactive bladder (OAB).

Study design, materials and methods

Thirty two women with OAB were treated with antimuscarinic agent (solifenacin) fixed dose (5mg) for 2weeks. Patients who had dry mouth were given artificial saliva agent (Taliva, HANLIM PHARM. CO. LTD, KR) to spray as often as required after 2weeks taking anti-muscarinic agents. Patients were asked to complete OAB symptom score (OABSS), patient perception of bladder condition (PPBC), International prostate symptom score questionnaire (IPSS) & QoL, and xerostomia questionnaire in first, second, and sixth weeks visit.

Results

Of the 20 women who had dry mouth after 2weeks, 10 (50%) completed the study; 10 were dropped out discontinuing anti-muscarinic agent due to other complications and ineffectiveness. OABSS(8.60 ± 3.06 vs. 5.70 ± 2.91), PPBC(4.00 ± 0.47 vs. 3.60 ± 0.52), IPSS(14.50 ± 4.80 vs. 10.20 ± 3.46) & QoL(3.70 ± 1.16 vs. 2.90 ± 0.32) and xerostomia questionnaire were improved in first 2weeks. However, total score of xerostomia questionnaire(13.90 ± 4.91 vs. 14.50 ± 5.91) were increased compare to baseline and 4 weeks after using artificial saliva agents. The symptom scores were improved overall in 6 weeks of OABSS, PPBS, IPSS & QoL scores (Table 1.).


Interpretation of results

Artificial saliva agent isn't helpful for dry mouth due to antimuscarinic agent.

Concluding message

Spray type of artificial saliva agent did not improve dry mouth after using antimuscarinic agent.

Table 1. Results.



References

1. 12. Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJUI 2012;110:1767-74.
2. P. HOOPER, D.G. TINCELLO and D.H. RICHMOND, The use of salivary stimulant pastilles to improve compliance, British Journal of Urology (1997), 80, 414–416
3. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99

Disclosures

Funding: None **Clinical Trial:** Yes **Public Registry:** No **RCT:** No **Subjects:** HUMAN **Ethics Committee:** Hanyang University Guri Hospital Institutional Review Board **Helsinki:** Yes **Informed Consent:** Yes